Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 4Not yet recruiting 2Completed 2Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Refractory or Relapsed Solid Tumors 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 60Magnetic Resonance Spectroscopy 43Carboplatin 33Cyclophosphamide 31Gemcitabine 28Biopsy 26Cisplatin 25pembrolizumab 24Bevacizumab 24Paclitaxel 23Injections 22Standard of Care 21Radiotherapy 21Drug Therapy 21Capecitabine 21fludarabine 20venetoclax 19Oxaliplatin 19toripalimab 17Nivolumab 17Interviews as Topic 17Dexamethasone 17Blood Specimen Collection 16anlotinib 15Radiosurgery 15tislelizumab 14Azacitidine 14cemiplimab 13Pemetrexed 13Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Itraconazole × 90 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡